Your browser doesn't support javascript.
loading
Pregnancy Termination and Postnatal Major Congenital Heart Defect Prevalence After Introduction of Prenatal Cardiac Screening.
Tomek, Viktor; Jicínská, Hana; Pavlícek, Jan; Kovanda, Jan; Jehlicka, Petr; Klásková, Eva; Mrázek, Jirí; Cutka, David; Smetanová, Dagmar; Bresták, Miroslav; Vlasín, Pavel; Pavlíková, Markéta; Chaloupecký, Václav; Janousek, Jan; Marek, Jan.
Afiliação
  • Tomek V; Children's Heart Centre, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, the Czech Republic.
  • Jicínská H; Department of Pediatric Cardiology, The University Hospital Brno, Faculty of Medicine of Masaryk University, Brno, the Czech Republic.
  • Pavlícek J; Department of Pediatrics and Prenatal Cardiology, University Hospital Ostrava, Ostrava, the Czech Republic.
  • Kovanda J; Children's Heart Centre, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, the Czech Republic.
  • Jehlicka P; Department of Pediatrics, University Hospital in Pilsen, Charles University, Pilsen, the Czech Republic.
  • Klásková E; Department of Pediatrics, Olomouc University Hospital and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, the Czech Republic.
  • Mrázek J; Department of Pediatrics, Masaryk Hospital, Ústí nad Labem, the Czech Republic.
  • Cutka D; Centre for Medical Genetics, Ceské Budejovice, the Czech Republic.
  • Smetanová D; Gennet, Centre for Fetal Medicine and Reproductive Genetics, Prague, the Czech Republic.
  • Bresták M; Department of Obstetrics and Gynecology of the First Faculty of Medicine, Charles University and General University Hospital, Prague, the Czech Republic.
  • Vlasín P; Fetal Medicine Center, Brno, the Czech Republic.
  • Pavlíková M; Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, the Czech Republic.
  • Chaloupecký V; Children's Heart Centre, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, the Czech Republic.
  • Janousek J; Children's Heart Centre, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, the Czech Republic.
  • Marek J; Great Ormond Street Hospital for Children and Institute of Cardiovascular Sciences UCL, London, United Kingdom.
JAMA Netw Open ; 6(9): e2334069, 2023 09 05.
Article em En | MEDLINE | ID: mdl-37713196
Importance: Prenatal cardiac screening of the first and second trimesters has had a major impact on postnatal prevalence of congenital heart defects (CHDs), rates of termination of pregnancy (TOP), and outcomes among children born alive with CHDs. Objective: To examine the prenatal and postnatal incidence of major CHDs (ie, necessitating intervention within the first year of life), detection rate trends, rates of TOP, and the association of cardiac screening with postnatal outcomes. Design, Settings, and Participants: In this cross-sectional study, 3827 fetuses with antenatally diagnosed major CHDs in the Czech Republic (population 10.7 million) between 1991 and 2021 were prospectively evaluated with known outcomes and associated comorbidities. Prenatal and postnatal prevalence of CHD in an unselected population was assessed by comparison with a retrospective analysis of all children born alive with major CHDs in the same period (5454 children), using national data registry. Data analysis was conducted from January 1991 to December 2021. Main Outcomes and Measures: Prenatal detection and postnatal prevalence of major CHDs and rate of TOPs in a setting with a centralized health care system over 31 years. Results: A total of 3 300 068 children were born alive during the study period. Major CHD was diagnosed in 3827 fetuses, of whom 1646 (43.0%) were born, 2069 (54.1%) resulted in TOP, and 112 (2.9%) died prenatally. The prenatal detection rate increased from 6.2% in 1991 to 82.8% in 2021 (P < .001). Termination of pregnancy decreased from 70% in 1991 to 43% (P < .001) in 2021. Of 627 fetuses diagnosed in the first trimester (introduced in 2007), 460 were terminated (73.3%). Since 2007, of 2066 fetuses diagnosed in the second trimester, 880 (42.6%) were terminated, resulting in an odds ratio of 3.6 (95% CI, 2.8-4.6; P < .001) for TOP in the first trimester compared with the second trimester. Postnatal prevalence of major CHDs declined from 0.21% to 0.14% (P < .001). The total incidence (combining prenatal detection of terminated fetuses with postnatal prevalence) of major CHD remained at 0.23% during the study period. Conclusions and Relevance: In this cross-sectional study, the total incidence of major CHD did not change significantly during the 31-year study period. The prenatal detection of major CHD approached 83% in the current era. Postnatal prevalence of major CHD decreased significantly due to early TOPs and intrauterine deaths. The introduction of first trimester screening resulted in a higher termination rate in the first trimester but did not revert the overall decreasing trend of termination for CHDs in general.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aborto Induzido / Cardiopatias Congênitas Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Child / Female / Humans / Pregnancy Idioma: En Revista: JAMA Netw Open Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aborto Induzido / Cardiopatias Congênitas Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Child / Female / Humans / Pregnancy Idioma: En Revista: JAMA Netw Open Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos